RxDoctor Payments Data

Stephen Vobach, MD

Psychiatry · Dallas, TXNPI 1851377006

Payments from drug & device makers

$277,980in general payments, 2019–2025

Across 1,766 payments — averaging $157.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$128K
  • Supernus Pharmaceuticals, Inc.$34K
  • Eisai Inc.$33K
  • Vanda Pharmaceuticals Inc.$26K
  • Idorsia Pharmaceuticals US Inc$15K
  • Takeda Pharmaceuticals U.S.A., Inc.$14K
  • plus $28K from 34 others

What the payments were for

  • Consulting fees$14,0505%
  • Speaking & faculty fees$222,48380%
  • Travel & lodging$13,3125%
  • Food & beverage$27,82610%
  • Education$3070%
  • Gifts$30%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$277,980 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$73,483
Medicare patients
289
Services billed
794

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide232$141,161
IngrezzaValbenazine Tosylate17$138,528
VraylarCariprazine Hcl47$83,001
RexultiBrexpiprazole24$38,457
VyvanseLisdexamfetamine Dimesylate39$18,395
QuviviqDaridorexant Hcl19$10,087
DayvigoLemborexant28$10,047
Desvenlafaxine Succinate ErDesvenlafaxine Succinate243$9,819
Duloxetine Hcl500$9,675
Lurasidone Hcl32$9,274
Lisdexamfetamine Dimesylate37$7,521
Vilazodone Hcl80$6,045
Alprazolam558$5,492
Quetiapine Fumarate254$5,295
BelsomraSuvorexant12$5,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$14,410$159,556271 claims
Neurocrine Biosciences, Inc.Ingrezza$1,572$138,52817 claims
AbbVieVraylar$128,472$83,00147 claims
Otsuka America Pharmaceutical, Inc.Rexulti$3,068$38,45724 claims
Idorsia Pharmaceuticals US IncQuviviq$14,989$10,08719 claims
Eisai Inc.Dayvigo$32,613$10,04728 claims
MerckBelsomra$155$5,15612 claims
Almatica Pharma LLCSertraline Hcl$587$2,066277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →